Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 16/20 | 0.60 |
| ▸ | MEN1 | O00255 | 14/20 | 0.60 |
| ▸ | NPC1 | O15118 | 10/20 | 0.60 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.60 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.60 |
| ▸ | ECE2 | P0DPD6 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 6/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 6/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 2/20 | 0.51 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.50 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12281168 | 0.86 | KMT2A (0.59) | KMT2AMEN1NPC1AGTR1HSP90AA1 | |
| SCHEMBL27470619 | 0.81 | KMT2A (0.68) | KMT2AMEN1NPC1AGTR1HSP90AA1 | |
| SCHEMBL19076207 | 0.81 | KMT2A (0.68) | KMT2AMEN1NPC1AGTR1HSP90AA1 | |
| SCHEMBL12281443 | 0.79 | KMT2A (0.62) | KMT2AMEN1NPC1AGTR1HSP90AA1 | |
| SCHEMBL12281839 | 0.77 | AGTR1 (0.79) | KMT2AMEN1NPC1AGTR1HSP90AA1 | |
| SCHEMBL14681421 | 0.77 | KMT2A (0.60) | KMT2AMEN1NPC1AGTR1HSP90AA1 | |
| SCHEMBL12281824 | 0.76 | MEN1 (0.75) | KMT2AMEN1NPC1AGTR1HSP90AA1 | |
| SCHEMBL19076263 | 0.76 | KMT2A (0.65) | KMT2AMEN1NPC1AGTR1HSP90AA1 | |
| SCHEMBL12281247 | 0.75 | KMT2A (0.69) | KMT2AMEN1NPC1AGTR1HSP90AA1 | |
| SCHEMBL12281165 | 0.75 | MEN1 (1.00) | KMT2AMEN1NPC1AGTR1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130225610-A1 | ANTIMETASTATIC COMPOUNDS | HANSEN MARC (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225610-A1 | ANTIMETASTATIC COMPOUNDS | HANSEN MARC (US) | 2013-08-29 | — | — | US | disclosed |
| US-8481553-B2 | Antimetastatic compounds | BRIGHAM YOUNG UNIVERSITY (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481553-B2 | Antimetastatic compounds | BRIGHAM YOUNG UNIVERSITY (US) | 2013-07-09 | — | — | US | disclosed |
| US-20130035348-A1 | ANTIMETASTATIC COMPOUNDS | BRIGHAM YOUNG UNIVERSITY (US) | 2013-02-07 | — | — | US | disclosed |
| US-20130035348-A1 | ANTIMETASTATIC COMPOUNDS | BRIGHAM YOUNG UNIVERSITY (US) | 2013-02-07 | — | — | US | disclosed |
| WO-2011127192-A2 | ANTIMETASTATIC COMPOUNDS | BRIGHAM YOUNG UNIVERSITY (US) | 2011-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225610-A1 | ANTIMETASTATIC COMPOUNDS | MET, HGFAC, HGF | KMT2A 3928/4885MEN1 391/4885NPC1 1073/4885 |
| US-20130035348-A1 | ANTIMETASTATIC COMPOUNDS | MET, HGFAC, HGF | KMT2A 3928/4885MEN1 391/4885NPC1 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.